BRAF and melanoma: Pharmacological inhibition of BRAF with vemurafenib and MEK with PD0325901 markedly reduced basal phospho-ERK (pERK) in melanoma cells while increasing SOX2, and this induction was specific to the inhibitor treatment as it was time dependent (Figure 1).